QGEN) decreased 0.51% in after-market trading after the company reported Q2 results.
Earnings per share rose 66.67% over the past year to $0.55, which beat the estimate of $0.46.
Revenue of $443,252,000 higher by 16.15% year over year, which beat the estimate of $425,820,000.
Earnings guidance hasn’t been issued by the company for now.
View more earnings on QGEN” data-reactid=”22″>View more earnings on QGEN
Qiagen hasn’t issued any revenue guidance for the time being.
52-week high: $50.97
52-week low: $25.04
Price action over last quarter: Up 11.57%
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company’s sales are split almost evenly between applications in life sciences (52% of 2019 sales) and molecular diagnostics (48% of sales). Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm’s revenue (47%), followed by EMEA (32%) and Asia-Pacific (21%).
View Article Origin Here